Daphne Stewart, MD

As resistance to endocrine and CDK4/6 inhibitor therapy grows, elacestrant offers a promising targeted option for patients with ESR1 mutations driving treatment failure.

The EMERALD trial evaluated elacestrant, an oral SERD, as a potential new standard for patients with ER+/HER2– advanced breast cancer resistant to prior endocrine therapies.